BioCentury
ARTICLE | Company News

DiaGenic diagnostic news

February 25, 2013 8:00 AM UTC

DiaGenic said in its 4Q12 report that it has terminated research activities and related employment positions outside of product development targeting Alzheimer's disease. DiaGenic said the move will reduce the company's cost base by about NOK3 million ($540,901) in 2013. The company said on its website that it will not make new investments in blood-based diagnostics PDtect for Parkinson's disease and BCtect for breast cancer and is evaluating opportunities for partnering or divesting the tests. DiaGenic's pipeline now consists of diagnostic tests MCItect for early AD detection at the mild cognitive impairment stage; the blood-based ADtect test for mild to moderate AD that measures the expression of 20 genes; and the blood-based AMYtect test for brain amyloid detection. MCItect is in clinical testing in the U.S. and ADtect has completed a validation study. AMYtect is being developed under a partnership with the GE Healthcare unit of General Electric Co. (NYSE:GE, Fairfield, Conn.). DiaGenic could not be reached for details (see BioCentury, April 2, 2012). ...